相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。B cell-activating factor and its targeted therapy in autoimmune diseases
Yidan Zhang et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2022)
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
Iris M. Otani et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial
Mary Rensel et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
Panos Stathopoulos et al.
NEUROTHERAPEUTICS (2022)
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Romain Marignier et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma
James A. Davis et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
Akinao Okamoto et al.
BLOOD ADVANCES (2022)
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Monica Margoni et al.
JOURNAL OF NEUROLOGY (2022)
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
Massimiliano Gambella et al.
FRONTIERS IN IMMUNOLOGY (2022)
CD20+ T cells: an emerging T cell subset in human pathology
Adrian Y. S. Lee
INFLAMMATION RESEARCH (2022)
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
Yusuke Miyazato et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2022)
Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
Romy Mosch et al.
FRONTIERS IN IMMUNOLOGY (2022)
New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases
Mei Sing Ong et al.
RHEUMATOLOGY (2022)
Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients
Francesca Schena et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
Jerome Avouac et al.
LANCET RHEUMATOLOGY (2021)
Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey
Nobuhisa Akamatsu et al.
TRANSPLANTATION DIRECT (2021)
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease
Reza Zonozi et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus A Randomized Controlled Trial
Muhammad Shipa et al.
ANNALS OF INTERNAL MEDICINE (2021)
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study
Laura N. Walti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency
Jin Yan Yap et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2021)
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties
Martijn Vlaming et al.
SCIENTIFIC REPORTS (2021)
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
Michael Markus Bonelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
Anna Furlan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients
Roxane Labrosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Use of rituximab in paediatric nephrology
Rajiv Sinha et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2021)
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease
Jeffrey A. Sparks et al.
CURRENT OPINION IN RHEUMATOLOGY (2021)
X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Report and an Overview of Literature
Mosopefoluwa Lanlokun et al.
FRONTIERS IN PEDIATRICS (2021)
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
Jonathan C. Strefford et al.
BLOOD ADVANCES (2021)
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Malgorzata Nowicka et al.
BLOOD ADVANCES (2021)
Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience
Gerasimos Evangelatos et al.
RHEUMATOLOGY (2021)
Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia
Giorgio Ottaviano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy
Alice Combier et al.
RHEUMATOLOGY (2020)
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
Khalaf Kridin et al.
AUTOIMMUNITY REVIEWS (2020)
Effects of rituximab therapy on B cell differentiation and depletion
L. Bergantini et al.
CLINICAL RHEUMATOLOGY (2020)
Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature
Chiara Zanetta et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
Sonia Boyer-Suavet et al.
FRONTIERS IN IMMUNOLOGY (2020)
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
Isabella Quinti et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Hepatitis B Virus Reactivation Potentiated by Biologics
Eiichi Ogawa et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19
Thomas Hueso et al.
BLOOD (2020)
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Lennard Ostendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
Francesca Compagno et al.
FRONTIERS IN IMMUNOLOGY (2020)
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma
Haoli Jin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Despoina Florou et al.
BRAIN SCIENCES (2020)
Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
Laura S. van Dam et al.
FRONTIERS IN IMMUNOLOGY (2020)
Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
Li Liu et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
B cells in chronic graft-versus-host disease
William McManigle et al.
HUMAN IMMUNOLOGY (2019)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values
Pierluigi Marzuillo et al.
WORLD JOURNAL OF CLINICAL CASES (2019)
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Amer M. Khojah et al.
PEDIATRIC RHEUMATOLOGY (2019)
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders
Luis Malpica et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
B cell targeted therapies in autoimmune disease
Jennifer L. Barnas et al.
CURRENT OPINION IN IMMUNOLOGY (2019)
Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis
Tamara H. Ramwadhdoebe et al.
RHEUMATOLOGY (2019)
Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational Study
Kevin L. Winthrop et al.
ARTHRITIS CARE & RESEARCH (2019)
Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern
Michael Gernert et al.
ARTHRITIS RESEARCH & THERAPY (2019)
B-Cell Therapy for Multiple Sclerosis: Entering an Era
Ariele L. Greenfield et al.
ANNALS OF NEUROLOGY (2018)
A tale of two antibodies: obinutuzumab versus rituximab
Ciara L. Freeman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors
Tobias Alexander et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution
Keith A. Sacco et al.
IMMUNOTHERAPY (2018)
Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment
Isabelle Meyts et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2018)
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL
I. Parodis et al.
LUPUS (2018)
Primary Sjogren's Syndrome
Xavier Mariette et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Andrew I. Rutherford et al.
RHEUMATOLOGY (2018)
Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors
Emiliano Marasco et al.
ARTHRITIS & RHEUMATOLOGY (2018)
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
Edward A. Clark et al.
FRONTIERS IN IMMUNOLOGY (2018)
Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring
Claire Leibler et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Monitoring B-cell repopulation after depletion therapy in neurologic patients
Erik Ellwardt et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
Sara Barmettler et al.
JAMA NETWORK OPEN (2018)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
Evangelos A. A. Christou et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy
John F. Beausang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
Current perspective on rituximab in rheumatic diseases
Tommaso Schioppo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets
E. Becerra et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome
Shuichiro Fujinaga et al.
CLINICAL NEPHROLOGY (2016)
Features of Human CD3+CD20+ T Cells
Elisabeth Schuh et al.
JOURNAL OF IMMUNOLOGY (2016)
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus Pooled Analyses From the Phase III Belimumab Trials
Ronald F. van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Antiviral prophylaxis in patients with solid tumours and haematological malignancies-update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
Michael Sandherr et al.
ANNALS OF HEMATOLOGY (2015)
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
Thomas Doerner et al.
AUTOIMMUNITY REVIEWS (2015)
Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab-for how long?
Sara Barmettler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
Darren M. Roberts et al.
JOURNAL OF AUTOIMMUNITY (2015)
Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series
Darren M. Roberts et al.
JOURNAL OF AUTOIMMUNITY (2015)
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2015)
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study
Federico De Angelis et al.
LEUKEMIA RESEARCH (2015)
Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
Jennifer Worch et al.
CANCERS (2015)
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
Andrew T. Vaughan et al.
BLOOD (2014)
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Helena Marco et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?
Fatima Dhalla et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes
M. Makatsori et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2014)
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function
E. G. Kamburova et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
Corey Cutler et al.
BLOOD (2013)
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
Sif Gudbrandsdottir et al.
BLOOD (2013)
Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
DeepakBabu Chellapandian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Carla Casulo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma
C. Keane et al.
INTERNAL MEDICINE JOURNAL (2012)
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
Inmaculada De La Torre et al.
RHEUMATOLOGY (2012)
Rituximab resistance
Andrew R. Rezvani et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Manfred Ahlgrimm et al.
BLOOD (2011)
Does rituximab increase the incidence of infectious complications? A narrative review
Theodoros Kelesidis et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms
Daniel Tesfa et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc gamma RIIIa 158(V/F) polymorphism
Szu-Chin Li et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial
Clifton O. Bingham et al.
ARTHRITIS AND RHEUMATISM (2010)
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
Jacek Bil et al.
BLOOD (2010)
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
Henrik E. Mei et al.
BLOOD (2010)
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2010)
Late-Onset Neutropenia After Rituximab Treatment Case Series and Comprehensive Review of the Literature
Ofir Wolach et al.
MEDICINE (2010)
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2009)
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
Magda Nakou et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Rituximab and intravenous immune globulin for desensitization during renal transplantation
Ashley A. Vo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice
Jean-David Bouaziz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Rare-event analysis in flow cytometry
Albert D. Donnenberg et al.
CLINICS IN LABORATORY MEDICINE (2007)
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
Jennifer H. Anolik et al.
CLINICAL IMMUNOLOGY (2007)
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma
Mitsufumi Nishio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab
M Tokunaga et al.
RHEUMATOLOGY (2005)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)